Eli Lilly & Co. has filed a patent infringement suit against Watson Pharmaceuticals Inc. over the rival drugmaker’s plans to market a generic version of postmenopausal osteoporosis treatment Evista®. The complaint argues that Watson’s abbreviated new drug application to market generic Evista® will lead to direct infringement of three patents. Lilly has previously sued several generic makers and successfully blocked Teva from launching generic Evista®. Lilly is represented in this matter by Finnegan.